MeHarish BioSim is a specialized consulting and subject matter expert (SME) firm dedicated to the biological safety and chemical evaluation of medical devices and pharmaceutical products. Led by a seasoned principal consultant with deep regulatory and scientific expertise, MeHarish BioSim provides focused advisory services across Toxicology Risk Evaluation, Biocompatibility Assessment, Biological and Chemical Evaluation, and Gap Analysis — strictly in a consulting and strategic planning capacity. The firm operates at the intersection of science and regulatory strategy, helping clients navigate complex compliance landscapes with precision and confidence.

Every engagement at MeHarish BioSim is driven by a commitment to scientifically rigorous, standards-aligned outcomes. Whether conducting a Toxicological Risk Assessment (TRA) in line with ISO 10993-17, developing a Biological Evaluation Plan (BEP) or Report (BER) per ISO 10993-1, characterizing extractables and leachables under ISO 10993-18, or identifying critical regulatory gaps and remediation pathways, the firm delivers actionable, audit-ready documentation tailored to each client's unique product and regulatory context. MeHarish BioSim serves medical device manufacturers, biotech companies, and regulatory affairs teams seeking expert-level SME guidance — without the overhead of a research institution.